Molecular imprinting as a tool for determining molecular markers: a lung cancer case.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
14 Jun 2022
14 Jun 2022
Historique:
received:
21
03
2022
accepted:
23
05
2022
entrez:
29
6
2022
pubmed:
30
6
2022
medline:
30
6
2022
Statut:
epublish
Résumé
Determining which cancer patients will be sensitive to a given therapy is essential for personalised medicine. Thus, it is important to develop new tools that will allow us to stratify patients according to their predicted response to treatment. The aim of work presented here was to use molecular imprinting for determining the sensitivity of lung cancer cell lines to ionising radiation based on cell surface proteomic differences. Molecularly imprinted polymer nanoparticles (nanoMIPs) were formed in the presence of whole cells. Following trypsinolysis, protein epitopes protected by complexing with MIPs were eluted from the nanoparticles and analysed by LC-MS/MS. The analysis identified two membrane proteins, neutral amino acid transporter B (0) and 4F2 cell-surface antigen heavy chain, the abundance of which in the lung cancer cells could indicate resistance of these cells to radiotherapy. This proof-of-principle experiments shows that this technology can be used in the discovery of new biomarkers and in development of novel diagnostic and therapeutic tools for a personalised medicine approach to treating cancer.
Identifiants
pubmed: 35765329
doi: 10.1039/d2ra01830f
pii: d2ra01830f
pmc: PMC9200412
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17747-17754Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts of interest to declare.
Références
Biochim Biophys Acta. 2015 Dec;1856(2):189-210
pubmed: 26297204
Mol Cancer Res. 2013 Sep;11(9):967-72
pubmed: 23788634
RSC Adv. 2022 Feb 1;12(7):3957-3968
pubmed: 35425427
Nano Lett. 2017 Apr 12;17(4):2307-2312
pubmed: 28350162
Trends Microbiol. 2006 Jan;14(1):15-21
pubmed: 16356720
Proteomics. 2008 Apr;8(7):1415-28
pubmed: 18306176
Biochim Biophys Acta. 1976 Apr 30;458(1):73-107
pubmed: 779852
Exp Hematol. 2003 Jan;31(1):11-30
pubmed: 12543103
Nano Lett. 2018 Aug 8;18(8):4641-4646
pubmed: 29969563
Int J Mol Sci. 2015 Nov 10;16(11):26880-913
pubmed: 26569225
BMC Microbiol. 2005 Oct 07;5:58
pubmed: 16212653
Clin Cancer Res. 2013 Feb 1;19(3):560-70
pubmed: 23213057
Biochim Biophys Acta. 1976 Nov 11;455(1):152-62
pubmed: 990323
Expert Rev Mol Diagn. 2019 May;19(5):409-417
pubmed: 30977684
Radiother Oncol. 2005 Aug;76(2):129-34
pubmed: 16024122
Chem Soc Rev. 2016 Apr 21;45(8):2137-211
pubmed: 26936282
J Cell Biol. 1983 Apr;96(4):1168-71
pubmed: 6339528
J Proteomics. 2014 Jan 31;97:164-76
pubmed: 23624344
Radiother Oncol. 2013 Sep;108(3):440-445
pubmed: 23891097
Front Chem. 2014 Aug 11;2:61
pubmed: 25157349
Langmuir. 2020 Jan 14;36(1):279-283
pubmed: 31829602
Radiat Oncol. 2016 Sep 06;11(1):115
pubmed: 27600665
Br J Cancer. 2014 Apr 15;110(8):2030-9
pubmed: 24603303
J Proteomics. 2012 Oct 22;75(18):5654-66
pubmed: 22842152
Adv Mater. 2021 Jul;33(30):e2100543
pubmed: 34145950
Methods Enzymol. 2017;590:115-141
pubmed: 28411635
Int J Biochem Cell Biol. 2012 Jun;44(6):955-62
pubmed: 22433988